Stock HCM HUTCHMED (CHINA) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. HUTCHMED (China) Limited Nasdaq

Equities

HCM

US44842L1035

Delayed Nasdaq
Other stock markets
 12:26:46 2024-05-24 EDT 		5-day change 1st Jan Change
18.79 USD +0.37% Intraday chart for HUTCHMED (China) Limited -6.84% +3.75%
12:00am HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology CI
05-20 Hutchmed (China) Chairman Resigns, Successor Named MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Deutsche Bank Upgrades HUTCHMED to Buy From Hold, Adjusts Price Target to $22.10 From $20
MT
Goldman Sachs Adjusts Price Target on HUTCHMED (China) to $17 From $15, Maintains Neutral Rating
MT
Hutchmed Says Platelet Disorder Drug Increased Durable Response Rate in Phase 3 Trial
MT
Goldman Sachs Adjusts HUTCHMED (China)'s Price Target to $16 From $14, Maintains Neutral Rating
MT
AstraZeneca Says Lung Cancer Combination Therapy Showed 49% Objective Response Rate
MT
AstraZeneca's Lung Cancer Drug Combo Shows 49% Objective Response Rate in Mid-stage Trial
MT
Hutchmed Says Phase 2 Study to Treat Patients With MET-Driven Non-Small Lung Cancer Shows Improved Response Rates
MT
Deutsche Bank Downgrades HUTCHMED to Hold From Buy, Adjusts Price Target to $20 From $37
MT
HUTCHMED CHINA : Goldman Sachs Downgrades Hutchison China MediTech to Neutral From Buy
MT
HUTCHMED CHINA : Jefferies Initiates Hutchison China MediTech at Buy Rating With $52 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HCM Stock
  4. HCM Stock
  5. News HUTCHMED (China) Limited
  6. Analyst Reco.